This “INVELTYS Drug Insight and Market Forecast - 2032” report provides comprehensive insights about INVELTYS for acute ocular pain (AOP) in the United States. A detailed picture of the INVELTYS for acute ocular pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INVELTYS market forecast analysis for acute ocular pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.
Drug Summary
INVELTYS (loteprednol etabonate/KPI-121) is a nanoparticle ocular corticosteroid formulation for treating postoperative ocular inflammation and pain. INVELTYS, as with other ophthalmic corticosteroids, is contraindicated in most cornea and conjunctiva viral diseases, including epithelial Herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
Mechanism of action
Loteprednol etabonate is a corticosteroid, and corticosteroids have been shown to inhibit the inflammatory response to various inciting agents.
Dosage
The suspension is shaken for 1-2 s before use. One to two drops of INVELTYS are instilled into the affected eye twice daily, beginning the day after surgery and continuing throughout the first 2 weeks of the postoperative period.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the INVELTYS description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
- Elaborated details on INVELTYS regulatory milestones and other development activities have been provided in this report.
- The report also highlights the INVELTYS research and development activities in acute ocular pain across the United States.
- The report also covers the patents information with expiry timeline around INVELTYS.
- The report contains forecasted sales of INVELTYS for acute ocular pain till 2032.
- Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
- The report also features the SWOT analysis with analyst views for INVELTYS in acute ocular pain.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
INVELTYS Analytical Perspective
In-depth INVELTYS Market Assessment
This report provides a detailed market assessment of INVELTYS for acute ocular pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
INVELTYS Clinical Assessment
The report provides the clinical trials information of INVELTYS for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVELTYS dominance.
- Other emerging products for acute ocular pain are expected to give tough market competition to INVELTYS and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVELTYS in acute ocular pain.
- This in-depth analysis of the forecasted sales data of INVELTYS from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INVELTYS in acute ocular pain.
Key Questions
- What is the product type, route of administration and mechanism of action of INVELTYS?
- What is the clinical trial status of the study related to INVELTYS in acute ocular pain and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INVELTYS development?
- What are the key designations that have been granted to INVELTYS for acute ocular pain?
- What is the forecasted market scenario of INVELTYS for acute ocular pain?
- What are the forecasted sales of INVELTYS in the United States?
- What are the other emerging products available and how are these giving competition to INVELTYS for acute ocular pain?
- Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?
This product will be delivered within 2 business days.
